LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND
) f+ V" e6 b% u' {5 r' Z; TTHERAPE UTIC PERSPECTIVES
# V" q/ P- n5 b# FJ. Mazieres, S. Peters* X* E5 C% ~% I/ X7 p! c
Introduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
, t9 m" u& h: f$ _3 Aoutcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted9 Y8 K( _! H+ t
treatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2# b% F1 t' i7 f, T5 ]
treatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations
, w. U$ e) B' n9 p! g0 j2 Q. xand 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;
% F2 ^* w" G2 ~disease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for0 t9 [$ R6 g$ F c
trastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to
/ O& V: Z8 H- N: h; a7 W; llapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and; ]+ h% |5 n' C8 r
22.9 months for respectively early stage and stag e IV patients.* D. ~9 v+ x; u
Conclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,
! S3 o9 l4 P: X3 ]' C$ hreinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .8 |/ x8 h: ]! c7 ?; [& f
HER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative
$ J1 o. B3 C5 D5 K( T+ lclinicaltrials.
7 |! @6 X% {! U) z: P4 L1 Y |
显身卡
